Heavy reliance upon praziquantel for the treatment of schistosomiasis raises concerns over potential development of drug resistance. We describe a British traveller who acquired Schistosoma mansoni infection in East Africa and in whom repeated standard 40 mg/kg doses of praziquantel failed to clear the infection despite no opportunity for reinfection.